Multimodal Therapy of Upper Gastrointestinal Malignancies

• Andere auteurs: Ronellenfitsch, Ulrich (Redacteur)
• Formaat: Elektronisch Hoofdstuk
• Taal: Engels
• Gepubliceerd in: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Onderwerpen: Public health & preventive medicine; gastric cancer; gastrectomy; complications; outcome; survival; lymph node ratio; neoadjuvant chemotherapy; conversion surgery; cancer dormancy; nuclear receptor NR2F1; clinical pathways; gastric surgery; oncological gastrectomy; quality of care; outcomes; standardization; adjuvant therapy; gastrointestinal tract; genetic diagnosis; radiosensitivity; mortality; failure to rescue; immunotherapy; genetics; esophageal cancer; multidisciplinary; gastric/gastroesophageal cancer; perioperative chemotherapy; overall survival; relapse-free survival; skeletal muscle index; esophagectomy; nutritional status; sarcopenia; esophageal anastomosis; minimally invasive surgery; induction chemotherapy; chemo-radiotherapy; neoadjuvant treatment; esophageal squamous cell carcinoma; multimodal treatment; neoadjuvant chemoradiotherapy; definitive chemoradiotherapy; Lauren histotype; gastrointestinal stromal tumor; neuroendocrine tumor; MALT lymphoma; mucosal resection; submucosal dissection; GIST; stomach; neoadjuvant therapy; imatinib; organ preservation; squamous cell esophageal cancer; gastro-esophageal reflux disease; Barrett's esophagus; early adenocarcinoma of esophagus; endoscopic submucosal dissection; endoscopic mucosal resection; n/a
• Online toegang: DOAB: download the publication; DOAB: description of the publication

Recent decades have seen remarkable advances in the treatment of upper gastrointestinal malignancies, i.e., adenocarcinoma and squamous cell carcinoma as well as gastrointestinal stromal and other rare tumors of the esophagus and stomach. While, historically, surgical resection has been the sole tre...